SODIUM CHLORIDE 0.9% INJ 9MG/ML USP LIQUID

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SODIUM CHLORIDE

Disponibbli minn:

MCGAW INC.

Kodiċi ATC:

B05XA03

INN (Isem Internazzjonali):

SODIUM CHLORIDE

Dożaġġ:

9MG

Għamla farmaċewtika:

LIQUID

Kompożizzjoni:

SODIUM CHLORIDE 9MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

500 ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

REPLACEMENT PREPARATIONS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0100053002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

1998-04-08

Karatteristiċi tal-prodott

_0.9% Sodium Chloride Injection USP Prescribing Information _
_Page 1 of 10_
PRESCRIBING INFORMATION
0.9% SODIUM CHLORIDE INJECTION USP
Solution, Intravenous
IV Fluid and Electrolyte Replenisher
B. BRAUN MEDICAL INC. Date of Preparation:
824 Twelfth Avenue
August 24, 2020
Bethlehem, PA 18018-3524 USA
Distributed by:
B. BRAUN OF CANADA, LTD.
2000 Ellesmere Road, Unit 16
Scarborough, Ontario M1H 2W4
Submission Control No: 235120
_ _
_0.9% Sodium Chloride Injection USP Prescribing Information _
_Page 2 of 10_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3
1
INDICATIONS ...............................................................................................................
3
1.1
PEDIATRICS ............................................................................................................
3
1.2
GERIATRICS ............................................................................................................
3
2
CONTRAINDICATIONS ..............................................................................................
3
3
DOSAGE AND ADMINISTRATION ...........................................................................
3
3.1
DOSING CONSIDERATIONS ....................................................................................
3
3.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ........................................... 4
3.3
ADMINISTRATION ...................................................................................................
4
4
OVERDOSAGE ............................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............... 5
6
WARNINGS AND PRECAUTIONS ............................................................................
6
6.1
SPECIAL POPULATIONS ..........................................................................................
7
6.1.1
PREGNANT WOMEN .....................................................